Cocrystal Pharma, Inc. (OTCBB:COCP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
|
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers |
On May 30, 2017, Cocrystal Pharma, Inc. (the Company) entered
into an agreement with James J. Martin to serve as the Companys
Chief Financial Officer on a full-time, non-interim basis
beginning June 1, 2017. As previously disclosed, Mr. Martin has
been serving as the Companys interim Chief Financial Officer as
an independent contractor since February 27, 2017.
Mr. Martin will be paid an annual salary of $230,000. At the
discretion of the Companys board of directors, Mr. Martin will
also be eligible to receive bonus compensation and equity awards.
Mr. Martins employment is on an at-will basis, pending the
negotiation of a mutually acceptable employment agreement between
the Company and Mr. Martin.
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits.
| Exhibit No. | Exhibit | |
| 10. 1 | James Martin Offer Letter |
About Cocrystal Pharma, Inc. (OTCBB:COCP)
Cocrystal Pharma, Inc., formerly Biozone Pharmaceuticals, Inc., is engaged in developing medicines for use in the treatment of human viral diseases. The Company develops technologies and approaches to create antiviral drug candidates. The Company is developing antiviral therapeutics that inhibit the replication function of a virus, including the ribonucleic acid (RNA)-dependent RNA polymerase enzyme, the helicase enzyme and the NS5A protein of hepatitis C virus (HCV), and the polymerase enzymes of influenza virus and norovirus. The polymerase inhibitors include both nucleosides (Nucs) and non-nucleosides. Its platform consists of computation, medicinal chemistry, click chemistry and X-ray crystallography. The Company determines the structures of cocrystals containing the inhibitors bound to the enzyme or protein to guide its design. The Company uses computational methods to screen and design product candidates using its cocrystal structural information. Cocrystal Pharma, Inc. (OTCBB:COCP) Recent Trading Information
Cocrystal Pharma, Inc. (OTCBB:COCP) closed its last trading session up +0.005 at 0.205 with 389,550 shares trading hands.